Oncology Clinical Trials Market Forecast
Global Oncology Clinical Trials Market reached US$ 32.5 billion in 2025 and is expected to reach US$ 68.5 billion by 2035, growing at a CAGR of 7.9% during the forecast period 2026-2035.
The global oncology clinical trials market is undergoing a phase of renewed momentum, driven by scientific innovation, rising cancer prevalence, and sustained investment in drug development.
In 2024, oncology trial activity showed a modest resurgence with over 2,160 new trial starts, reflecting renewed confidence after recent operational slowdowns. Trial designs are increasingly focused on rare cancers and solid tumors, addressing high unmet clinical needs. Geographically, there is a clear shift toward single-country trials, with China playing a pivotal role in expanding domestic oncology research capacity. Multi-country oncology studies now represent only a small share of new trial initiations, signaling a more regionally concentrated development strategy.
Clinical trial productivity in oncology has improved by more than 50% since 2019, supported by better trial design, biomarker integration, and data analytics. Despite these gains, oncology development still faces efficiency challenges compared to other therapeutic areas due to disease complexity and patient heterogeneity.
A key growth driver is the rapid expansion of PD-1/PD-L1 inhibitors, which are increasingly used as first-line therapies and in earlier disease stages, particularly in high-income markets. This shift is broadening patient eligibility and improving long-term survival outcomes.
Investment momentum remains strong, with global cancer medicine spending reaching $252 billion in 2024 and projected to rise sharply by 2029. New drug launches, wider access, and adoption of advanced modalities such as antibody–drug conjugates and bispecific antibodies continue to fuel market expansion.
Emerging technologies are further transforming clinical trials, with AI tools, liquid biopsies, and spatial profiling improving patient selection, response prediction, and trial success rates. Looking ahead, continued technological integration, regional trial expansion, and precision oncology approaches are expected to drive sustained growth and reshape the future of the global oncology clinical trials market.
Oncology Clinical Trials Market Key Takeaways
- Precision oncology is increasing the complexity and value of clinical trials through biomarker selection and molecular profiling.
- Immunotherapy remains a major driver of oncology clinical research, while targeted therapies and advanced treatment combinations continue expanding.
- Cell and gene therapies, antibody-drug conjugates, bispecific antibodies and radioligand therapies are creating new clinical-trial opportunities.
- Phase III trials remain a major value segment, while Phase I activity is expanding with the introduction of novel therapeutic modalities.
- Adaptive, basket and biomarker-driven trials are improving development flexibility for targeted oncology programs.
- Hybrid and decentralized trial components are reducing patient burden and creating additional recruitment opportunities.
- AI is becoming increasingly important for patient matching, site selection, trial monitoring and data analysis.
- Patient recruitment remains one of the largest operational challenges, particularly for biomarker-defined trials.
- Real-world evidence and post-marketing studies are becoming increasingly important for demonstrating long-term treatment performance.
- Specialized CRO capabilities are becoming more valuable as oncology protocols require complex laboratory, imaging, regulatory and patient-management services.
- Personalized cancer vaccines represent an emerging high-potential trial category, with increasing clinical development activity.
- North America remains a major clinical-research hub, while Asia-Pacific offers strong expansion opportunities.
- The competitive landscape is shifting toward integrated clinical-development ecosystems combining CRO services, technology, data and specialized oncology expertise.
Oncology Clinical Trials Market Scope
| Metrics | Details |
| CAGR | 7.9% |
| Market Size Available for Years | 2025-2035 |
| Estimation Forecast Period | 2026-2035 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Phase Type, Study Design, Cancer Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Oncology Clinical Trials Market Dynamics: Drivers & Restraints
Rising Incidence of Cancer Cases
The rising global incidence of cancer is a significant catalyst for the expansion of the oncology clinical trials market. According to the International Agency for Research on Cancer (IARC), there were nearly 20 million new cancer cases worldwide in 2022. This number is projected to increase by 77% by 2050, reaching about 35 million new cases annually.
Lung cancer remains the most commonly diagnosed, accounting for around 12.4% of all cases, followed by breast cancer at 11.6% and colorectal cancer at 9.6%. Breast cancer alone is expected to reach 3.2 million new cases annually by 2050. These rising cancer rates, fueled by aging populations, lifestyle factors, and environmental influences, create an urgent demand for improved diagnostics and treatments.
To meet this challenge, the number of oncology clinical trials has risen, with 2,162 new trials initiated in 2024, a 12% increase from 2019, focusing especially on rare cancers and solid tumors.
Clinical research organizations (CROs) play a vital role in managing these trials. There were 4,321 Contract Research Organizations in the US businesses as of 2024, an increase of 2.1% from 2023.
The expanding burden of cancer worldwide is thus directly increasing clinical trial activity, enabling researchers and healthcare providers to find new, more effective therapies that can better save and improve the lives of cancer patients globally.
Complicated conditions and targeted treatments
Cancer treatment is moving toward more targeted therapies: As researchers identify cancer molecular pathways and targets, it is becoming possible to treat the target tumour regardless of the organ of origin. More targeted therapies may change which patients and cancers may benefit, since a given treatment may only impact very specific biomarkers and genetic profiles.
Oncology Clinical Trials Market Trends & Insights
Precision Oncology Is Increasing Trial Complexity
Oncology clinical trials are increasingly incorporating biomarker testing, genomic profiling, companion diagnostics and molecularly defined patient populations. This improves patient selection but also increases screening, laboratory and data-management requirements.
Immunotherapy Continues to Reshape Oncology Trials
Immunotherapy remains one of the most important therapeutic modalities in oncology research, while combinations with targeted therapies, chemotherapy and other immunotherapies are creating increasingly complex clinical-development programs.
Cell and Gene Therapy Trials Are Expanding
Cell and gene therapies are creating new opportunities for oncology clinical research, particularly in hematological malignancies and selected solid tumors. These studies require specialized manufacturing, logistics, patient monitoring and long-term follow-up.
Phase I Oncology Research Is Becoming More Innovative
Early-stage oncology trials are increasingly evaluating antibody-drug conjugates, bispecific antibodies, radioligand therapies, personalized cancer vaccines, cell therapies and other novel modalities. This is increasing demand for specialized early-phase trial infrastructure.
Adaptive and Basket Trial Designs Are Gaining Importance
Adaptive designs allow researchers to modify certain trial elements based on emerging data, while basket trials evaluate a therapy across multiple cancers sharing a molecular or biological characteristic. These designs can improve development efficiency for precision oncology programs.
Decentralized and Hybrid Trial Models Are Expanding
Hybrid clinical trials combine conventional site-based visits with remote procedures such as electronic consent, telemedicine, remote patient monitoring and home-based assessments. These approaches can improve patient convenience and broaden recruitment opportunities.
AI Is Improving Patient Recruitment and Trial Operations
AI-enabled technologies are increasingly being used for patient identification, eligibility screening, site selection, protocol feasibility, data analysis and trial monitoring. These applications can reduce administrative workloads and improve operational efficiency.
Real-World Data Is Becoming More Important
Real-world evidence is increasingly being incorporated into oncology development to complement clinical-trial findings, understand treatment patterns and support long-term safety and effectiveness assessment.
Personalized Cancer Vaccines Are Creating a New Trial Category
Personalized cancer vaccines based on individual tumor characteristics are becoming an important emerging area of oncology research. Increasing clinical development activity in personalized cancer vaccines is attracting greater attention from pharmaceutical and biotechnology companies.
Biomarker-Driven Patient Recruitment Is Becoming Essential
Molecular testing is increasingly used to identify patients most likely to respond to targeted therapies. This improves trial precision but creates additional requirements for genomic testing, sample management and specialized recruitment networks.
Multi-Regional Trials Are Expanding
Pharmaceutical and biotechnology companies are increasingly conducting multi-country oncology trials to access larger patient populations, accelerate recruitment and support simultaneous regulatory strategies.
Post-Marketing Oncology Research Is Growing
Phase IV studies and long-term follow-up programs are becoming increasingly important for evaluating real-world safety, durability of treatment response, quality of life and outcomes across broader patient populations.
Oncology Clinical Trials Market Segment Analysis
The global oncology clinical trials market is segmented based on phase type, study design, cancer type, end user and region.
Phase III from the phase type segment accounted for approximately 43.3%. of the oncology clinical trials market share
Phase III from the phase type segment accounted for approximately 43.3%. Phase III oncology clinical trials involve rigorous testing of experimental treatments in a large patient population to confirm their effectiveness and safety. Trends in this phase include personalized medicine, focusing on biomarkers for targeted therapies, and collaboration between industry and regulatory bodies to streamline processes and expedite the translation of promising treatments from research to clinical end user.
For instance, in January 2024, Merck announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.
Oncology Clinical Trials Market Geographical Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the favourable reimbursement policies, and the presence of major market players in the region, leading to investment and the development of innovative products. Also, the U.S. FDA has a fast-track approval process for drugs that treat cancer. Moreover, an increase in R&D in the area and government funding also help the region to grow during the forecast period.
For instance, in February 2024, the National Institutes of Health launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network (CSRN) will support the Biden-Harris administration’s Cancer Moonshot by investigating how to identify cancers earlier, when they may be easier to treat. Eight groups have received funding from the National Cancer Institute (NCI), part of NIH, to carry out the initial activities of the network.
Oncology Clinical Trials Market Regulatory & Compliance Trends
Global Regulatory Harmonization
Greater alignment of clinical-trial requirements can facilitate multi-regional oncology development.
Data Integrity
Increasing use of digital systems makes data validation, traceability and cybersecurity important trial requirements.
Patient-Centric Research
Regulators and sponsors are placing greater emphasis on patient experience, quality of life and meaningful clinical outcomes.
Advanced Therapy Oversight
Cell, gene and personalized therapies require additional considerations related to manufacturing, chain of identity, long-term monitoring and patient safety.
Oncology Clinical Trials Market Competitive Landscape
The major global players in the market include AstraZeneca, Merck & Co., Inc, Gilead Sciences, Inc, F. Hoffmann-La Roche Ltd, Syneos Health, Daiichi Sankyo Company, Eli Lilly and Company, PharmaMar, Novocure, Pfizer Inc among others.
Key Developments in the Oncology Clinical Trials Market
- August 2026: AstraZeneca continued expanding its oncology clinical-development pipeline, with late-stage studies across lung, breast, gastrointestinal and hematologic cancers supporting the company's strategy of advancing targeted therapies and immuno-oncology treatments.
- August 2026: Merck & Co., Inc. continued advancing KEYTRUDA-based combination studies, including trials evaluating pembrolizumab with other targeted and antibody-drug therapies across multiple tumor types.
- July 2026: Gilead Sciences, Inc. continued expanding oncology clinical development through its cell-therapy and targeted-therapy portfolio, with ongoing trials evaluating next-generation treatments for hematologic and solid tumors.
- July 2026: F. Hoffmann-La Roche Ltd. continued advancing its oncology pipeline through clinical trials evaluating personalized medicines, antibody-drug conjugates, immunotherapies and targeted treatments across a broad range of cancers.
- July 2026: Daiichi Sankyo Company, Limited continued expanding clinical development of its antibody-drug conjugate (ADC) portfolio, with multiple late-stage studies targeting breast, lung and other cancers.
- June 2026: Eli Lilly and Company continued progressing oncology clinical trials across targeted therapies and combination treatments, with particular emphasis on lung cancer, breast cancer and gastrointestinal cancers.
- June 2026: Pfizer Inc. continued expanding its oncology pipeline through clinical studies of targeted therapies, antibody-drug conjugates and immunotherapies, while generating additional evidence for recently launched cancer treatments.
- June 2026: Novocure continued advancing clinical research involving Tumor Treating Fields (TTFields), evaluating the technology across glioblastoma, lung cancer, pancreatic cancer and other solid-tumor indications.
- May 2026: Syneos Health continued expanding its oncology clinical-trial services, supporting pharmaceutical and biotechnology companies with clinical development, patient recruitment, decentralized-trial capabilities and real-world evidence programs.
- May 2026: PharmaMar continued advancing its oncology pipeline through clinical development of marine-derived anticancer compounds, with ongoing research targeting solid tumors and other difficult-to-treat cancers.
- April 2026: AstraZeneca continued strengthening its oncology trial portfolio through combination studies involving immunotherapies, targeted therapies and antibody-drug conjugates, reflecting the industry's move toward precision and biomarker-driven treatment.
Why Choose DataM?
Technological Innovations: DataM evaluates advances in AI-enabled patient recruitment, precision oncology platforms, biomarker testing, genomic profiling, decentralized and hybrid trials, remote patient monitoring, electronic clinical outcomes, centralized imaging and advanced clinical-trial analytics.
Product Performance & Market Positioning: The report evaluates clinical-trial providers and technologies based on recruitment efficiency, geographic reach, therapeutic expertise, data quality, technology integration, regulatory capabilities, trial execution and cost efficiency.
Real-World Evidence: DataM connects market developments with oncology clinical research across lung, breast, colorectal, prostate, leukemia and other cancers, while assessing the increasing role of biomarkers, real-world data and long-term patient outcomes.
Market Updates & Industry Changes: The report tracks clinical-trial registrations, regulatory developments, novel therapeutic modalities, CRO expansion, technology adoption, decentralized trials, AI integration, strategic collaborations and emerging oncology research models.
Competitive Strategies: DataM analyzes how leading CROs, pharmaceutical companies, biotechnology companies and clinical-trial technology providers strengthen their positions through specialized oncology services, global site networks, patient-recruitment technologies, strategic partnerships and integrated clinical-development solutions.
Pricing & Market Access: DataM evaluates clinical-trial economics based on study phase, patient recruitment, number of sites, geographic coverage, biomarker testing, imaging, treatment complexity, technology requirements, CRO services and trial duration.
Market Entry & Expansion: DataM identifies opportunities created by precision oncology, advanced therapies, decentralized trial models, AI-enabled recruitment, expanding Asia-Pacific research capabilities, specialized CRO services and increasing pharmaceutical investment in oncology.
Target Audience
- Pharmaceutical & Biotech Companies – Clinical development strategy.
- CROs – Service and expansion opportunities.
- Clinical Research Organizations – Trial execution insights.
- Diagnostic Companies – Biomarker and companion-diagnostic opportunities.
- Investors – Oncology pipeline and market intelligence.
- Technology Providers – Clinical-trial technology opportunities.
- Research Institutes – Oncology research trends.
The global oncology clinical trials market report would provide approximately 64 tables, 61 figures and 186 pages.
